News from Nanoscope
Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa
“We expect to begin the first randomized, double-masked Phase 2b multi-center optogenetic trial in the US this summer to confirm our gene therapy’s ability to improve vision in RP patients. If successful, it will be the first-ever cure for millions of RP patients worldwide.” said Nanoscope CEO Sulagna Bhattacharya.
Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.